NeoGenomics Inc (NEO): Revenue
$727.33M
Year ended 2025-12-31
$766.29M
Trailing 12 months to 2026-06-30
+12.6%
3-year compound annual growth
+10.4%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $727.33M | +10.1% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $660.57M | +11.6% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $591.64M | +16.1% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $509.73M | +5.2% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $484.33M | +9.0% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $444.45M | +8.7% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $408.83M | +47.7% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $276.74M | +15.2% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $240.25M | +3.6% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $231.81M | n/a | 2019-02-26, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| NeoGenomics Inc (NEO) | 2025-12-31 | $727.33M | +10.1% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $2.53B | +20.0% |
| UL Solutions Inc. (ULS) | 2025-12-31 | $3.05B | +6.4% |
| NRC Health (NRC) | 2025-12-31 | $137.39M | -4.0% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $4.02B | -0.9% |
| Incyte Corp (INCY) | 2025-12-31 | $5.14B | +21.2% |
| Icon PLC (ICLR) | 2025-12-31 | $8.25B | +0.8% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $33.03M | -14.5% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $16.31B | +5.9% |
Compare NEO, MEDP, ULS, NRC side by side · Screen every company in Services-Testing Laboratories ↗